Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer

Trial Profile

Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Mar 2018 Planned End Date changed from 1 Jul 2020 to 1 Jul 2021.
    • 09 Mar 2018 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2020.
    • 13 Feb 2018 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top